Follow Us

Law.com Subscribers SAVE 30%

Call 855-808-4530 or email [email protected] to receive your discount on a new subscription.

Intellectual Property Patent Licensing and Transactions

Treatment of Antibody Claims In the U.S. After 'Amgen v. Sanofi'

The future of antibody claiming in the United States is uncertain following the U.S. Supreme Court’s May 2023 ruling in Amgen Inc. v. Sanofi, a highly anticipated decision concerning enablement and whether the traditional way to claim antibodies — claiming antibodies by their function — will survive as a valid claiming strategy.

X

Thank you for sharing!

Your article was successfully shared with the contacts you provided.

The future of antibody claiming in the United States is uncertain following the U.S. Supreme Court’s May 2023 ruling in Amgen Inc. v. Sanofi, 598 U.S. 594 (2023), a highly anticipated decision concerning enablement and whether the traditional way to claim antibodies — claiming antibodies by their function — will survive as a valid claiming strategy.

This premium content is locked for The Intellectual Property Strategist subscribers only

Continue reading by getting
started with a subscription.

ENJOY UNLIMITED ACCESS TO THE SINGLE SOURCE OF OBJECTIVE LEGAL ANALYSIS, PRACTICAL INSIGHTS, AND NEWS FOR INTELLECTUAL PROPERTY LAW PRACTITIONERS.
  • Stay current on the latest information, rulings, regulations, and trends
  • Includes practical analysis of developments in patent, copyright and trademark law
  • Tap into expert guidance from top intellectual property lawyers and experts

SUBSCRIBE NOW

Subscribe Now For Unlimited Access

Read These Next